DakoCytomation signs agreement on novel prostate cancer markers

11-Sep-2003

CARPINTERIA, CA, US - DakoCytomation has received exclusive worldwide rights to two antibodies that hold promise for prostate cancer diagnostics and monitoring. Under a licensing agreement with immunotherapeutics developer Corixa Corporation (Nasdaq: CRXA), in vitro diagnostics leader DakoCytomation will have the exclusive right to develop and commercialize immunohistochemistry diagnostics and right to develop therapeutic drug monitoring products related to two markers known as P504S and P501S.

P504S is a tumor specific marker and P501S is specific for prostate tissue.

"These new antibodies will allow us to strengthen our portfolio of products for managing patients with prostate cancer", said Dennis Chenoweth, Corporate Vice President of Diagnostics for DakoCytomation. "Our goal continues to be optimizing care for patients with all types of cancer."

DakoCytomation will use Corixa's antibodies to develop tests for diagnostic use. The eventual goal is to expand the company's portfolio of diagnostic tests for managing patients with prostate cancer and to help physicians link diagnostic assay results to specific therapies and treatment outcomes.

Prostate cancer is the most common non-skin cancer found in men and the second leading cause of cancer deaths in men. The World Health Organization estimates some 250,000 new cases of prostate and testicular cancer are diagnosed globally each year.

Other news from the department science

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures